Publication | Open Access

Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials

VaccinationVaccine SafetyOpen Label PhaseHeterologous SchemeVaccine DevelopmentImmunologyMedicineIia Clinical TrialsCovid-19